SENATE, No. 2647

STATE OF NEW JERSEY
220th LEGISLATURE

INTRODUCED MAY 16, 2022

Sponsored by:
Senator EDWARD DURR
District 3 (Cumberland, Gloucester and Salem)

SYNOPSIS
Prohibits health care professional licensing boards from restricting or taking adverse disciplinary action for prescribing certain COVID-19 treatments.

CURRENT VERSION OF TEXT
As introduced.
AN ACT concerning certain prescribing practices and supplementing Title 45 of the Revised Statutes.

BE IT ENACTED by the Senate and General Assembly of the State of New Jersey:

1. a. As used in this section, “COVID-19” means coronavirus disease 2019 resulting from infection with the SARS-CoV-2 virus.
   b. In no case shall any board that issues licenses or certifications to practice a health care profession in New Jersey:
      (1) restrict health care professionals from prescribing the off-label use of a drug, device, or biological product for the prevention or treatment of COVID-19; or
      (2) take any adverse disciplinary action against a health care professional who issues a prescription for the off-label use of a drug, device, or biological product for the prevention or treatment of COVID-19.

2. This act shall take effect immediately.

STATEMENT

This bill prohibits boards that issue licenses or certifications to practice a health care profession in New Jersey from: 1) imposing restrictions on prescribing the off-label use of a drug, device, or biological product for the prevention or treatment of COVID-19; and 2) taking any adverse disciplinary action against a health care professional who issues a prescription for the off-label use of a drug, device, or biological product for the prevention or treatment of COVID-19.